Skip to main content
Premium Trial:

Request an Annual Quote

Lenetix to Co-market CombiMatrix MDx Tests

NEW YORK (GenomeWeb News) – CombiMatrix today said that its suite of array CGH-based tests will be co-marketed by New York-based diagnostics lab Lenetix.

The focus of the collaboration is CombiMatrix's suite of arrays for genetic conditions, primarily its BAC HD Scan test, which identifies more than 290 genomic causes of developmental disorders. Syndromes identified by the test include Down (trisomy 21), Prader-Willi, Smith Magenis, trisomy 13, trisomy 18, and DiGeorge syndromes, among others. The collaboration also includes CombiMatrix's Prenatal Scan array CGH test, a customized test specifically designed for use in prenatal diagnostics, said CombiMatrix.

"Our collaboration with Lenetix will help us increase awareness of our tests among primary care physicians including pediatricians, genetic counselors, and obstetricians-gynecologists — key customers of Lenetix," said Mansoor Mohammed, president and CEO of Combimatrix Molecular Diagnostics, in a statement.

Financial terms of the co-marketing pact were not disclosed.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.